BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 24 January, 2008
BIOTIE THERAPIES CORP. NOTIFICATION ACCORDING TO CHAPTER 2, SECTION 10 OF THE SECURITIES MARKETS ACT, 24 JANUARY, 2008
Biotie Therapies Corp. (the "Company") has on 24 January 2008 gained knowledge of the following change in holdings under Chapter 2, Section 9 of the Finnish Securities Market Act:
The aggregate holding of Pequot Healthcare Fund, L.P., Pequot Healthcare Offshore Fund, Inc., Premium Series PCC Limited - Cell 32, Pequot Diversified Master Fund, Ltd., Pequot Healthcare Institutional Fund, L.P. and Pequot Healthcare Emerging Markets Fund, Ltd. (jointly, the "Funds") remains above 25 % of the share capital and voting rights of the Company, as notified on 5 April 2007. Pequot Healthcare Emerging Markets Master Fund has decreased its holding from 5,01 % to 4,99 % of the voting rights and share capital in the Company, calculated on the basis of the number of shares registered in the Finnish Trade Register on 30 April 2007.
Pequot Healthcare Emerging Markets Master Fund has notified of a change in holdings under Chapter 2, Section 9 of the Securities Market Act due to which the Pequot Healthcare Emerging Markets Master Fund's holding has on 30 April 2007 decreased under 5 % of the voting rights in and number of shares of the Company due to an increase in the total number of shares of the Company. At present, said fund's holding is, according to the information received by the Company, as follows:
|
Shareholder |
Number of shares |
Proportion of
share capital and voting rights |
|
Pequot Healthcare Emerging Markets Master Fund, Ltd |
4.500.000 |
4.99 % |
The aggregate holdings of the Funds and their division between the Funds have been notified earlier in the notification on 5 April 2007.
The share capital of Biotie Therapies Corp. constitutes 90,211,860 shares in the aggregate and the number of voting rights attached to the shares amounts to 90,211,860.
Turku, on 24 January, 2008
Timo Veromaa
President and CEO
For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
DISTRIBUTION
OMX Nordic Exchange Helsinki
Main Media